Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HC, Saunders C, Cardoso F, Susnjar S, Bjelic-Radisic V, Smith KL, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O. Partridge AH, et al. Among authors: borstnar s. Breast. 2021 Oct;59:327-338. doi: 10.1016/j.breast.2021.07.021. Epub 2021 Aug 3. Breast. 2021. PMID: 34390999 Free PMC article.
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, Lu J, Ciruelos E, Azim HA, Chatterjee S, Zhou K, Wu J, Menon-Singh L, Zamagni C. De Laurentiis M, et al. Among authors: borstnar s. Breast Cancer Res Treat. 2021 Oct;189(3):689-699. doi: 10.1007/s10549-021-06334-0. Epub 2021 Aug 19. Breast Cancer Res Treat. 2021. PMID: 34414532 Free PMC article. Clinical Trial.
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
Borstnar S, Palacova M, Łacko A, Timcheva C, Gal-Yam EN, Papazisis K, Beniak J, Kudela P, Rubovszky G. Borstnar S, et al. Radiol Oncol. 2022 May 17;56(2):238-247. doi: 10.2478/raon-2022-0020. Radiol Oncol. 2022. PMID: 35575587 Free PMC article. Clinical Trial.
Invasive bladder cancer: our experience with bladder sparing approach.
Cervek J, Cufer T, Zakotnik B, Kragelj B, Borstnar S, Matos T, Zumer-Pregelj M. Cervek J, et al. Among authors: borstnar s. Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):273-8. doi: 10.1016/s0360-3016(98)00013-3. Int J Radiat Oncol Biol Phys. 1998. PMID: 9607341
50 results